HELIOS- A:A Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

Brief description of study

The purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis). Participants will receive vutrisiran or the reference comparator patisiran during the Treatment Period.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Hereditary Transthyretin Amyloidosis,hATTR Amyloidosis
Age: Between 18 Years - 85 Years
Gender: All

Male or female ; 18 to 85 years of age ; Has a diagnosis of hATTR amyloidosis with transthyretin (TTR) mutation;

Updated on 09 Mar 2024. Study ID: 832041

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).